Themis Medicare Share Price Target 2026 Analyst Forecast Bull and Bear Case

Themis Medicare (NSE: THEMISMED) is a Pharmaceutical Formulations and APIs company trading at Rs 121.25 with a market capitalisation of Rs 605 crore. Analysts have set the Themis Medicare share price target at Rs 145 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.

Click Here – Get Free Investment Predictions

Themis Medicare Share Price Target 2026: Key Takeaways

• Themis Medicare share price target 2026: Rs 145 (20% upside from CMP Rs 121.25)
• Bull case: Rs 175 | Bear case: Rs 97
• Ticker: THEMISMED | Sector: Pharmaceutical Formulations and APIs | MCap: Rs 605 crore
• 52W range: Rs 84 to Rs 199 | PE: 15x
• Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
• Key risk: FY27 earnings miss or FII outflows from Indian equities

Themis Medicare Company Overview

Themis Medicare (NSE: THEMISMED) is a Vapi-based pharmaceutical company manufacturing APIs, intermediates, and branded pharmaceutical formulations for domestic institutional supply and regulated export markets. At CMP Rs 121.25 against a 52 week range of Rs 84 to Rs 199, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 605 crore with trailing PE of 15x. Compared to peers in pharma APIs like Kilitch Drugs and Lincoln Pharmaceuticals, Themis Medicare is positioned as a potential re-rating candidate toward the Rs 145 price objective on FY27 earnings delivery.

Parameter	Value
NSE Ticker	THEMISMED
Sector	Pharmaceutical Formulations and APIs
CMP (2026)	Rs 121.25
52 Week High	Rs 199
52 Week Low	Rs 84
Market Cap	Rs 605 crore
Trailing PE	15x
12-Month Analyst Target	Rs 145
Bull Case Target	Rs 175
Bear Case Target	Rs 97

Why Is the Themis Medicare Share Price Target Set at Rs 145 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Themis Medicare share price target of Rs 145 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 121.25.

Structural Sector Tailwinds in Pharmaceutical Formulations and APIs

The Pharmaceutical Formulations and APIs sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Themis Medicare’s position among peers in pharma APIs like Kilitch Drugs and Lincoln Pharmaceuticals creates a structural growth runway. Sustained outperformance is one of the key conditions for the Rs 175 bull case to materialise.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Themis Medicare’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 145 analyst consensus.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Themis Medicare’s Pharmaceutical Formulations and APIs operations, improving the probability of achieving the Rs 145 price objective through FY27 earnings delivery.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 15x PE, Themis Medicare is positioned as a beneficiary of institutional reallocation toward the Rs 175 bull case over the medium term.

Themis Medicare Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Themis Medicare Share Price Target

Near-term support for Themis Medicare is anchored close to the 52 week low of Rs 84. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 121.25.

12-Month Themis Medicare Share Price Target 2026

The 12-month Themis Medicare share price target 2026 is Rs 145, implying approximately 20 percent upside from CMP Rs 121.25. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.

Long Term Themis Medicare Share Price Target: FY27 to FY28

The long term Themis Medicare share price target for FY27 to FY28 is Rs 175 in the bull case, requiring full earnings delivery, re-rating among peers in pharma APIs like Kilitch Drugs and Lincoln Pharmaceuticals, and sustained institutional buying over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Themis Medicare in 2026

Bull Case Themis Medicare Share Price Target: Rs 175

The bull case Themis Medicare share price target of Rs 175 materialises when FY27 earnings beat analyst estimates, Pharmaceutical Formulations and APIs tailwinds accelerate, and FII flows return strongly to Indian equities. From CMP Rs 121.25, this represents approximately 45 percent potential upside.

Bear Case Themis Medicare Share Price Target: Rs 97

The bear case Themis Medicare share price target of Rs 97 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 84.

Scenario	Target	Key Conditions
Bull Case	Rs 175	FY27 beat, sector re-rating, FII inflows
Base Case (Analyst Target)	Rs 145	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 97	FY27 miss, guidance cut, FII outflows persist

Key Risks That Could Derail the Themis Medicare 2026 Price Objective

Global Macro and US Tariff Headwinds

Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Themis Medicare share price target of Rs 145, with FII outflows being the direct transmission mechanism to Indian equity valuations.

FY27 Earnings Miss and Guidance Risk

An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 145 analyst price objective. Investors must monitor quarterly results and management commentary closely.

Competitive Intensity Among Pharmaceutical Formulations and APIs Peers

Intensifying competition from peers in pharma APIs like Kilitch Drugs and Lincoln Pharmaceuticals could compress Themis Medicare’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 145 analyst target for 2026.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.

How to Invest in Themis Medicare

Check the Univest Screener for live data

Before considering any investment based on the Themis Medicare share price target of Rs 145, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical Formulations and APIs sector demand.

Open a Demat account with a SEBI registered stockbroker to trade Themis Medicare (NSE: THEMISMED) with full regulatory protection. Study the competitive landscape among peers in pharma APIs like Kilitch Drugs and Lincoln Pharmaceuticals before executing any position.

Plan your entry using the 52 week low of Rs 84 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 145 price objective. Always set a stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Themis Medicare’s live share price and receive daily stock recommendations.

FAQs on Themis Medicare Share Price Target 2026

What is the Themis Medicare share price target for 2026?

Ans. The Themis Medicare share price target 2026 is Rs 145, implying approximately 20 percent upside from CMP Rs 121.25. Bull case is Rs 175, bear case is Rs 97.

What was the Themis Medicare share price target for 2025?

Ans. The 2025 price objective for Themis Medicare was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 145, reflecting FY27 growth potential from CMP Rs 121.25.

Is Themis Medicare a good investment at Rs 121.25?

Ans. At Rs 121.25, Themis Medicare offers potential upside toward Rs 145 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.

What are the key risks to the Themis Medicare share price target 2026?

Ans. Key risks to the Themis Medicare share price target of Rs 145 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical Formulations and APIs. Monitoring quarterly results is essential.

What is the 52 week high and low of Themis Medicare?

Ans. The 52 week high of Themis Medicare is Rs 199 and the 52 week low is Rs 84. At CMP Rs 121.25, the stock offers potential upside toward the Rs 145 price objective.

What are the main growth catalysts for Themis Medicare in 2026?

Ans. Key catalysts include FY27 PAT recovery, Pharmaceutical Formulations and APIs tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Themis Medicare compare to its peers?

Ans. Themis Medicare operates in Pharmaceutical Formulations and APIs alongside peers in pharma APIs like Kilitch Drugs and Lincoln Pharmaceuticals. At CMP Rs 121.25 with MCap Rs 605 crore, it is a potential re-rating candidate toward the Themis Medicare share price target of Rs 145 on FY27 delivery.

What is the Themis Medicare share price target for 2027?

Ans. The long-term Themis Medicare share price target for FY27 to FY28 is Rs 175 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.